Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with biweekly XELOX/XELIRI in advanced colorectal cancer
NCT04324476Phase 2Unknown
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Sep 2019
- Primary completion
- Jul 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in colorectal cancer (CRC), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04324476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04324476.